Abstract: Compositions and methods for mucosal delivery of agents are provided. The emulsion compositions are intended for administration to a mucosal surface, such as oral, gastrointestinal and nasal mucosa. The emulsion compositions provided contain one or more mucoadhesive proteins and an agent to be delivered. Methods for delivery of agents using the compositions provided herein are also provided.

Abstract: The present invention provides a method for producing pentosan polysulfate, the method including a first step of obtaining an acidic xylooligosaccharide from a plant-derived raw material, and a second step of obtaining pentosan polysulfate from the acidic xylooligosaccharide. The first step includes a step of depolymerizing the plant-derived raw material. The second step includes a step of sulfating the acidic xylooligosaccharide. The method further includes a deacetylation step of adding a base to achieve a pH of 11 or higher. The deacetylation step is a step performed after the depolymerization step. The production method of the present invention can provide pentosan polysulfate having a low acetyl group content, and also produce pentosan polysulfate with a high yield inexpensively and efficiently.

Abstract: Poly alpha-1,3-glucan ester compounds are disclosed herein with a degree of substitution of about 0.001 to about 3.0. Also disclosed are methods of producing poly alpha-1,3-glucan ester compounds using cyclic organic anhydrides.

Abstract: The present invention relates to a method for the chlorination of a sucrose-6-acylate to produce a 4,1?,6?-trichloro-4,1?,6?-trideoxy-galactosucrose-6-acylate wherein said method includes steps of: (i) combining the sucrose-6-acylate with a chlorinating agent in a reaction vehicle comprising a tertiary amide to afford a mixture; (ii) heating said mixture for a heating period in order to provide chlorination of sucrose-6-acylate at the 4,1? and 6? positions thereof; and (iii) quenching the product stream of (ii) to produce a 4,1?,6?-trichloro-4,1?,6?-trideoxy-galactosucrose-6-acylate; wherein before said quenching, a portion of said tertiary amide is removed by extraction into a solvent in which said tertiary amide is at least partially soluble.

Abstract: The present disclosure provides certain combination therapy technologies that are particularly useful for treating one or more diseases, disorders, or conditions that may be related to abnormal metabolism. In some embodiments, provided technologies provides combinations of TCA cycle acids and ketone bodies. In some embodiments, provided technologies provides combinations of TCA cycle acids and other carboxylic acids.

Abstract: The present invention relates to a method for the chlorination of a sucrose-6-acylate to produce a 4,1?,6?-trichloro-4,1?,6?-trideoxy-galactosucrose-6-acylate wherein said method includes steps of: (i) combining the sucrose-6-acylate with a chlorinating agent in a reaction vehicle comprising a tertiary amide to afford a mixture; (ii) heating said mixture for a heating period in order to provide chlorination of sucrose-6-acylate at the 4, 1? and 6? positions thereof; and (iii) quenching the product stream of (ii) to produce a 4,1?,6?-trichloro-4,1?,6?-trideoxy-galactosucrose-6-acylate; wherein before said quenching, a portion of said tertiary amide is removed by extraction into a solvent in which said tertiary amide is at least partially soluble.

Abstract: The invention relates to a process for separation of organic acids from mixture of ammonium salts of one or more organic acids and other compounds via an integrated process. The process involves suspending mixture of ammonium salts of one or more organic acids and other compounds in dry hydrocarbon solvent/s or mixtures thereof; wherein the selected hydrocarbon solvent/s or mixtures thereof have boiling point more than 100° C. and forms an azeotrope with water. The reaction mixture thus obtained is dehydrated azeotropically followed by esterification of basic salt of the organic acids by addition of alcohol in presence of metal or metal salt; thereafter the individual esters formed are separated by distillation and hydrolyzed to obtain corresponding organic acids having more than 98% purity.

Abstract: A sterile injectable aqueous formulation in the form of a gel made up of hyaluronic acid or a salt thereof and one or more polyols is provided. The gel formulation can be applied to the intra-articular area in the treatment of joint degeneration and osteoarthritis. The gel formulation has a rheology similar to that of synovial liquid and has an elevated resistance to degradation due to the synergistic action between the hyaluronic acid and the polyols.

Abstract: Various methods are provided for treating and reacting a metathesis feedstock. In one embodiment, the method includes providing a feedstock comprising a natural oil, chemically treating the feedstock with a metal alkoxide under conditions sufficient to diminish catalyst poisons in the feedstock, and, following the treating, combining a metathesis catalyst with the feedstock under conditions sufficient to metathesize the feedstock.

Abstract: A process for the production of carbohydrate partial esters by transesterification of glycoses with fatty acid esters in the presence of emulsifiers and a catalyst mixture, to produce products with utility in the production of foods, cosmetic preparations, and in superabsorbancy applications.

Abstract: The present invention provides the use of cordycepin or derivatives thereof in manufacture of medicaments for antidepression, said derivatives mean pharmaceutically acceptable salts, esters of crodycepin or glycosides formed by cordycepin and saccharides.

Abstract: A rheology modifier which includes a mixture of short and long chain fatty acid esters is suitable for use in liquid surfactant-based compositions. A surfactant-based composition includes a surfactant, the rheology modifier, and water. The rheology modifier includes a mixture of alkyl glycoside fatty acid esters including a long chain fatty acid ester of an alkyl glycoside and a short chain fatty acid ester of an alkyl glycoside. The long chain fatty acid ester includes at least one fatty acid residue: R1(O)O—, wherein R1 is a C12 or higher hydrocarbon. The short chain fatty acid ester includes least one fatty acid residue: R2(O)O—, wherein R2 is a C6-C10 hydrocarbon.

Abstract: Disclosed is a flavor improving agent that is a fraction derived from fruit juice or squeeze. A fraction wherein the amount of substance ratio between polyphenols and saccharides, the latter after acid hydrolysis of the fraction, (polyphenol/saccharide) is 0.1-10, and even more preferably, wherein the amount of substance ratio of the polyphenol and the saccharide before acid hydrolysis of the fraction (polyphenol/saccharide) is 1-100, and is used as a flavor improving agent. Such fraction are obtained with a method such as by a fruit juice or squeeze being absorbed onto a synthetic resin adsorbent and the adsorbed components being eluted by a solvent, or by extracting fruit juice or squeeze with ethanol. The flavor improving agent has flavor improving effects such as suppressing sourness, bitterness and astringency of foods and beverages, reducing harsh taste, contributing to a juice-like feel and contributing to a richness.

Abstract: Solutions formed by combining poly(?(1?3) glucan) with concentrated aqueous formic acid solution, optionally containing methylene chloride, have been shown to produce the formylated form of the poly(?(1?3) glucan). The solutions so formed have been shown to be useful for solution spinning into fiber of poly(?(1?3) glucan) when the spun fiber is coagulated into a coagulation bath. The fibers so produced exhibit desirable physical properties. The poly(?(1?3) glucan) employed was synthesized by the action of a recombinant enzyme prepared via fermentation.

Abstract: The invention relates to the compounds of formula I, formula II and formula III or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II or formula III and methods for the treatment of cardiovascular and neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

Abstract: The invention provides novel compounds and formulations of turmeric oil, fish oil, aspirin and anti-cancer drugs (paclitaxel) having anti-inflammatory, analgesic and/or anti-cancer activity.

Abstract: Disclosed are methods for producing esterified propoxylated glycerols and eutectic mixtures containing one or more esterified propoxylated glycerols and one or more digestible fats. Food products containing the eutectic mixtures are also disclosed.

Abstract: One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyloidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.

Abstract: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease.

Abstract: Aspects of the invention relate to compounds, extracts and compositions thereof, and methods of using of the same, to treat neurodegenerative disorders and/or improve brain health. In certain embodiments, said compounds are pomegranate flavonoids.

Abstract: A method for the preparation of a sucrose-6-ester is disclosed. In a first step of the method, sucrose in a polar aprotic solvent is reacted with an organotin-based acylation promoter. The water of reaction is removed at a temperature that does not exceed about 80° C. In one aspect, the water is removed by distillation of part of the polar aprotic solvent at reduced pressure. In a second step, a carboxylic acid anhydride is added. In one aspect, the resulting reaction mixture is maintained at a temperature of 10° C. or less for a period of time sufficient to produce a sucrose-6-ester. The sucrose-6-ester can be converted to sucralose.

Abstract: A water soluble iron carbohydrate complex obtainable from an aqueous solution of iron(III) salt and an aqueous solution of the oxidation product of one or more maltrodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, a process for its production and a medicament for the treatment and prophylaxis of iron deficiency conditions.

Abstract: The present invention relates to a mutant, non-naturally occurring or transgenic plant cell comprising: (i) at least one polynucleotide comprising, consisting or consisting essentially of a sequence encoding an isopropylmalate synthase and having at least 60% sequence identity to SEQ ID NO:1 or SEQ ID NO:10 or SEQ ID NO: 12 or SEQ ID NO:14; or (ii) a polypeptide encoded by said polynucleotide(s); or (iii) a polypeptide having at least 60% sequence identity to SEQ ID NO:2 or SEQ ID NO:11 or SEQ ID NO:13 or SEQ ID NO:15; or (iv) a construct, vector or expression vector comprising said polynucleotide sequence(s), optionally wherein said construct, vector or expression vector additionally comprises a promoter comprising, consisting or consisting essentially of the sequence set forth in SEQ ID NO:8 or a variant thereof with at least about 60% identity thereto or a trichome promoter.

Abstract: Poly alpha-1,3-glucan ester compounds are disclosed herein with a degree of substitution of about 0.05 to about 3.0. Also disclosed are methods of producing poly alpha-1,3-glucan ester compounds and films made therefrom.

Abstract: Compositions containing a combination of hydroxytyrosol and resveratrol or liqustilide or (?)-epigallocatechin gallate or honokiol or genistein or Magnolia bark extract or a combination of oleuropein and resveratrol or ligustilide are used to treat inflammatory disorders.

Abstract: The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.

Abstract: The present invention relates to the use of a compound of formula (I): wherein: R represents a linear or branched alkyl group, comprising from 3 to 27 carbon atoms, said alkyl group being substituted with at least two hydroxyl groups, and which may optionally contain one or more unsaturations; and R? is selected from sugars or sugar-alcohols; for preparing polyurethanes and polyesters.

Abstract: A method that can be used to make a precursor of L-fucose from D-glucose that includes the steps of a) making a compound of formula (1) from D-glucose, formula (1) wherein R1 is acyloxy, and Q is a group (a), (b), (c) or (d), formula (a), (b), (c) or (d) or wherein R1 is OH, and Q is a group (e), (f) or (g); formula (e), (f) or (g) wherein R2 is acyloxy and R3 is a sulphonyl leaving group; and b) producing 6-deoxy-L-talose from the compound of formula (1) formed in step a), wherein the moiety is a highly lipophilic protecting group; compounds according to formula (1), and use of a compound according to formula (1) are provided.

Abstract: Disclosed is a method of chlorinating a carbohydrate or derivative thereof, for example, a sucrose-6-ester at the 4,1?, and 6? positions, with irreversible removal of HCl formed during the reaction to form the chlorinated carbohydrate or derivative thereof, for example, a 4,1?,6?-trichloro-4,1?,6?-trideoxy-6-O-ester of galactosucrose (TGS-6E). The irreversible removal of HCl can be carried out by an irreversible physical process and/or an irreversible chemical process. Sucralose, an artificial sweetener, can be prepared by deesterification of the TGS-6E. The chlorination reaction takes place at low temperatures and the desired chlorinated product is obtained in high yields and in high purities.

Abstract: The present invention relates to novel galactose derivatives of general formula (I) and their use as agents for stimulating the immune system of the skin and/or as immunoregulators, and for preparing a composition containing a cosmetically or pharmaceutically acceptable medium, intended in particular to prevent and/or limit the appearance of cutaneous immune imbalances, in particular related to environmental stresses.

Abstract: A method of removing a carboxylic acid from a liquid including a tertiary amide solvent includes: forming an extraction medium including an acid-extracting tin species and an extraction solvent that is immiscible with the tertiary amide solvent; subsequently contacting the liquid with the extraction medium, forming a phase including a de-acidified tertiary amide solvent and a phase including the extraction solvent; and removing the phase including the extraction solvent, to afford a liquid including the de-acidified tertiary amide solvent. The acid-extracting tin species is one or more tin species obtained by reaction of a di(hydrocarbyl) tin oxide with less than one equivalent of a carboxylic acid, or tin species obtainable by reaction of a 1,3-diacyloxy-1,1,3,3-tetra-(hydrocarbyl)distannoxane with an aqueous base. A method of preparing a sucralose-6-acylate includes uses the foregoing method to remove a carboxylic acid from a liquid including a tertiary amide solvent and the sucralose-6-acylate.

Abstract: Poly alpha-1,3-glucan ester compounds are disclosed herein with a degree of substitution of about 0.05 to about 3.0. Also disclosed are methods of producing poly alpha-1,3-glucan ester compounds and films made therefrom.

Abstract: Poly alpha-1,3-glucan ester compounds are disclosed herein with a degree of substitution of about 0.05 to about 3.0. Also disclosed are methods of producing poly alpha-1,3-glucan ester compounds and films made therefrom.

Abstract: A trehalose compound having high immunopotentiating activity and low toxicity is represented by formula (1). (In the formula, X and X? each represents a phenyl, a naphthyl, R1—CHR1— (wherein R1 and R2 each represents a C7-C21 alkyl group or the like) or the like; and n and n? each independently represents an integer of 0-3). The compound exhibits a high activating effect on macrophages and neutrophils.

Abstract: A method for producing a diester of polyhydric alcohol and fatty acid, comprising a step of reacting a monoester of polyhydric alcohol and fatty acid in the presence of a catalyst containing a hydrotalcite compound to obtain a diester of polyhydric alcohol and fatty acid.

Abstract: A method of determining the presence or absence in a sample of a biomarker, the method comprising: (a) linking an antigen to colloidal gold to provide a gold-antigen species; (b) contacting the gold-antigen species with the sample; (c) adding a diagnosis agent to the sample; and (d) observing the colour of the sample.

Abstract: Disclosed are methods for producing esterified propoxylated glycerols and eutectic mixtures containing one or more esterified propoxylated glycerols and one or more digestible fats. Food products containing the eutectic mixtures are also disclosed.

Abstract: Methods for purifying and extracting compounds from a mixture are provided using a solvent-free mechanochemical method. Methods for purifying and/or extracting sugars, amino acids, and, the like, from a mixture are also provided, using a solvent-free mechanochemical method.

Abstract: Disclosed herein are compositions that include a blend of sucrose polyesters, wherein each sucrose polyester includes a sucrose moiety and a plurality of fatty acid ester moieties, wherein a percentage range of the combined fatty acid ester moieties of the sucrose polyesters in the blend have a carbon chain that has trans content.

Abstract: Polysaccharide derivatives, more particularly heteropolysaccharide derivatives, especially hemicellulose derivatives, methods for making same and structures employing same are provided.

Abstract: The invention generally relates to the preparation of 18F-labeled radiopharmaceuticals. In particular, this invention relates to the advanced processes for an efficient eiution of [18F]fluoride trapped in a cartridge filled with quaternary ammonium polymer which comprises inert non-basic and non-nucleophilic counter anions. The said methods and polymer cartridges allow the rapid preparation of suitable [18F]fluoride solution, which is also less basic to reduce the formation of byproducts, finally to increase radiochemical yield and purity of 18F-radiopharmaceuticals.

Abstract: A method for synthesizing variants of Tre; novel Tre variants; and a method for introducing Tre in sufficient concentration into the intracellular environment suitable to store treated mammalian cells, treat an aggregation disease, and protect treated cells from oxygen radicals are disclosed.

Abstract: Methods for purifying and extracting compounds from a mixture are provided using a solvent-free mechanochemical method. Methods for purifying and/or extracting sugars, amino acids, and, the like, from a mixture are also provided, using a solvent-free mechanochemical method.

Abstract: One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyloidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.

Abstract: Surface-treated carboxyalkylated polysaccharides comprising a biobased content of at least 82% are described herein. The surface-treated carboxyalkylated polysaccharides comprise a CRC of at least 18 g/g, a FSC of at least 26 g/g, and an AUL at 0.7 psi of at least 14 g/g. Processes for the manufacture of surface-treated carboxyalkylated polysaccharides are also described herein.

Abstract: The present invention relates to the use of trisaccharide derivates comprising a substituted trisaccharide core, which trisaccharide core is fully substituted with fatty acid ester groups, and optionally one or more anionic groups as adjuvants, to the trisaccharide derivates as such, to a method for preparing such trisaccharides, to trisaccharides obtained with such method, to adjuvant compositions comprising such trisaccharide derivates and to a vaccine or kit comprising such adjuvant compositions.

Abstract: Pro-drugs of all non-steroidal anti-inflammatories with free acid function derivatized with an ester group, which have the general structural formula given below (I) where A is: aspirin, diflunisal, benorylate, ibufenac, diclofenac, indomethacin, sulindac, ketorolac, ibuprofen, naproxen, ketoprofen, fenoprofen, flurbiprofen, mefenamic acid, meclof enamic acid, flufenamic acid, niflumic acid, and where in the ester group R can be a sugar (amongst which aldose, or ketose pentose, or esose selected from a group of D- and L-enantioiuers of ribose, glucose, galactose, mannose, arabinose, xilose, allose, altrose, gulose, idose and talose and substituted derivatives thereof, such as glucosamine, galactosamine, N-acetyl glucosamine, N-acetyl galactosamine, N-acetyl ribosamine), a disaccharide, a trisaccharide or an oligosaccharide.

Abstract: The invention provides a method to prevent or treat HIV-infection with synthetic tannins, and pharmaceutical compositions comprising synthetic tannins.

Abstract: Method for producing L-fucose includes in a first aspect, a method for the preparation of L-fucose, wherein L-fucose precursors are produced from pectin and L-fucose is produced from the L-fucose precursors; in a second aspect, a method for the preparation of L-fucose from D-galacturonic acid or a salt thereof, wherein L-fucose precursors are produced from D-galacturonic acid of a salt thereof, and L-fucose is produced from the L-fucose precursors; and an L-fucose precursor as shown in Formula A, wherein R is a linear or branched chain saturated hydrocarbon group with 1-6 carbon atoms, such as methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-hexyl, etc., preferably a methyl group.

Abstract: Water soluble Iron carbohydrate complex obtainable from an aqueous solution of iron(III) salt and an aqueous solution of the oxidation product of one or more maltrodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, process for its production and medicament for the treatment and prophylaxis of iron deficiency conditions.